Report Description of the UK Psoriasis Market Analysis

Research Scope and Assumption

• The report provides the market value for the base year 2020 and a yearly forecast up to 2028 in terms of revenue (USD billion)


• The key industry dynamics, regulatory scenario, reimbursement scenario, major market trends, and drug markets are evaluated to understand their impacts on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis


• We have used the combination of top-down and bottom-up approach for market sizing, analyzing key regional markets, dynamics, and trends for various solutions, services, and end uses


• All market estimates and forecasts have been validated through primary interviews with the Key Industry Players (KIPs) and secondary analysis


• Inflation has not been accounted for in order to estimate and forecast the market


• Numbers may not add up due to rounding off

Reason to buy the report:

• Facilitate decision-making based on strong current and forecast data for UK Psoriasis Market Analysis


• Develop strategies based on the latest regulatory framework


• Strategically analyze micro-markets with respect to individual growth trends, future prospects, and their contribution to the market


• Analyze competitive developments such as expansions, investments, mergers & acquisitions, new product developments, and research & developments in the UK Psoriasis Market Analysis


• Analyze the opportunities in the market for stakeholders and draw a competitive landscape for market leaders


• To strategically profile key players and comprehensively analyze their market shares and core competencies


• We have technically sound team which do a deep dive research and also provide strategy based consulting analysis

UK Psoriasis Market Analysis Executive Summary

The health insurance system has been es-

tablished to guarantee public health in Japan

and Japan fortunately became the country

with the longest life expectancy in the world.

However, it has been forecasted that the ever-

growing medical expenses will upset the

health insurance system. In this paper, the

status quo of medical information systems is

outlined and the work on the electronic

health record which will also be the key to

the rationalisation of the medical system in

the near future is described.

The health insurance system has been es-

tablished to guarantee public health in Japan

and Japan fortunately became the country

with the longest life expectancy in the world.

However, it has been forecasted that the ever-

growing medical expenses will upset the

health insurance system. In this paper, the

status quo of medical information systems is

outlined and the work on the electronic

health record which will also be the key to

the rationalisation of the medical system in

the near future is described.

The health insurance system has been es-

tablished to guarantee public health in Japan

and Japan fortunately became the country

with the longest life expectancy in the world.

However, it has been forecasted that the ever-

growing medical expenses will upset the

health insurance system. In this paper, the

status quo of medical information systems is

outlined and the work on the electronic

health record which will also be the key to

the rationalisation of the medical system in

the near future is described.

The health insurance system has been es-

tablished to guarantee public health in Japan

and Japan fortunately became the country

with the longest life expectancy in the world.

However, it has been forecasted that the ever-

growing medical expenses will upset the

health insurance system. In this paper, the

status quo of medical information systems is

outlined and the work on the electronic

health record which will also be the key to

the rationalisation of the medical system in

the near future is described.

The health insurance system has been es-

tablished to guarantee public health in Japan

and Japan fortunately became the country

with the longest life expectancy in the world.

However, it has been forecasted that the ever-

growing medical expenses will upset the

health insurance system. In this paper, the

status quo of medical information systems is

outlined and the work on the electronic

health record which will also be the key to

the rationalisation of the medical system in

the near future is described.

The health insurance system has been es-

tablished to guarantee public health in Japan

and Japan fortunately became the country

with the longest life expectancy in the world.

However, it has been forecasted that the ever-

growing medical expenses will upset the

health insurance system. In this paper, the

status quo of medical information systems is

outlined and the work on the electronic

health record which will also be the key to

the rationalisation of the medical system in

the near future is described.

The health insurance system has been es-

tablished to guarantee public health in Japan

and Japan fortunately became the country

with the longest life expectancy in the world.

However, it has been forecasted that the ever-

growing medical expenses will upset the

health insurance system. In this paper, the

status quo of medical information systems is

outlined and the work on the electronic

health record which will also be the key to

the rationalisation of the medical system in

the near future is described.

The health insurance system has been es-

tablished to guarantee public health in Japan

and Japan fortunately became the country

with the longest life expectancy in the world.

However, it has been forecasted that the ever-

growing medical expenses will upset the

health insurance system. In this paper, the

status quo of medical information systems is

outlined and the work on the electronic

health record which will also be the key to

the rationalisation of the medical system in

the near future is described.

The health insurance system has been es-

tablished to guarantee public health in Japan

and Japan fortunately became the country

with the longest life expectancy in the world.

However, it has been forecasted that the ever-

growing medical expenses will upset the

health insurance system. In this paper, the

status quo of medical information systems is

outlined and the work on the electronic

health record which will also be the key to

the rationalisation of the medical system in

the near future is described.

Psoriasis can be defined as a skin condition, which accelerates the life cycle of skin cells. It results in cells to develop on the surface. It is usually considered to be a chronic condition. The condition has an unpredictable course of symptoms, significant comorbidities, and various external triggers impacting the condition that includes metabolic syndrome, arthritis, and cardiovascular diseases, among others. The immune system is considered to play an integral role in the condition. The condition also affects nails apart from skin. When a particular area on the skin is affected by the disease, the skin lesion is usually localized, which are sharply demarcated by plaques and red papules that are covered by silver or white scales. These lesions are generally symmetrical and cause stinging, itching, and pain. Herein the main aim of the treatment is to prevent the skin cells from growing quickly. There is no cure to the disease; however, these drugs help in managing the symptoms.

Market Size and Key Findings

The UK Psoriasis Market Analysis size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.



Market Dynamics

Market Growth Drivers Analysis

The growth of the Psoriasis Drugs market is majorly driven by factors such as increasing public awareness, approval of new drugs Onterleukin-17 inhibitor, Taltz - ixekizumab by Eli Lily), and boost in psoriasis Research and Development investment.

Market Restraints

The key restraints of the market are the high cost involved in drug development, patent expiry of brand name drugs, side effects from the systemic and biologics medication, and health insurance issue.

COVID-19 impact on "UK Psoriasis Market Analysis

The COVID-19 outbreak has no significant impact on the Psoriasis treatment market. According to the companies involved in the development and manufacturing of the Psoriasis treatment products, there is no significant impact on the sales of the products especially biologics in first quarter.

Competitive Landscape

Key Players

Prominent companies dominating the UK Psoriasis Drugs Market profiled in this report are Johnson & Johnson (USA), Novartis International AG (Switzerland), Pfizer Inc (USA), Merck and Co. Inc (USA), Celgene Corporation (USA), Janssen Biotech Inc (USA), Stiefel Laboratories Inc (USA), Takeda Pharmaceutical Company Limited (Japan), Amgen (USA), and AbbVie (USA).

Products in Pipeline

• May 2019 Mayne Pharma Group Limited announced that it has received FDA approval for the use of SORILUX Foam for the treatment of plaque psoriasis. The product is used in treatment of psoriasis of the body & scalp in patients aged 12 years and older.


• In February 2019, Janssen Pharmaceuticals, Inc. (Johnson & Johnson Services, Inc.) received FDA approval to use TREMFYA, One-Press a single-dose, patient controlled injector for the treatment of moderate-to-severe plaque psoriasis in adults.

Notable Recent Deals

• In August 2019, Amgen made an announcement to acquire Otezla, a firm involved in the production of psoriasis drugs, for a worth USD 13.40 billion.


• In August 2019, it was announced by Amgen, Inc. that it would acquire an oral drug permitted for moderate-to-severe plaque psoriasis, Apremilast (Otezla), for USD 13.4 billion from Celgene.

Healthcare Policies and Regulatory Landscape

Policy changes and Reimbursement scenario

A European Expert Working Group for Healthcare in Psoriasis (EEWGHP), comprising clinicians and patient advocacy group (PAG) representatives, was convened. The EEWGHP worked between June 2010 and December 2011 to outline the specific issues in psoriasis care, and start developing clear goals and actions that would help to address them.

The goals and actions set out in this White Paper are based on the opinions of the EEWGHP, formed from extensive experience in their specialist fields and supported by relevant clinical evidence, where possible. They aim to provide a framework for improving early access to high-quality care for people with psoriasis in Europe, through raised awareness and consistent management. Ultimately, it is hoped that this framework will help to raise treatment aspirations in psoriasis (of both healthcare professionals (HCPs) and people with psoriasis), thereby improving clinical outcomes and quality of life (QoL) for people with psoriasis.

NICE said Skyrizi will be available for use in the National Health Service by adult patients whose disease is severe, as determined by a score of 10 or more in the Psoriasis Area and Severity Index and Dermatology Life Quality Index tools used to measure the severity of psoriasis and impact of skin disease on the patient's quality of life, respectively.

The U.K. pricing authority's recommendation also covers patients whose disease has not responded to other systemic treatments, including ciclosporin, methotrexate and phototherapy, or in cases where these treatment options are contra-indicated or not tolerated.

Patients should stop taking Skyrizi if their psoriasis has not responded adequately after 16 weeks of treatment, NICE noted.